J Korean Med Sci.  2014 Feb;29(2):238-242. 10.3346/jkms.2014.29.2.238.

Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study

• Jin SM
• Song SO
• Jung CH
• Chang JS
• Suh S
• Kang SM
• Jung I
• Park CY
• Kim JH
• Cho JH
• Lee BW

• KMID: 1789981
• DOI: http://doi.org/10.3346/jkms.2014.29.2.238

Abstract

It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had > or = 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer.

Keyword

Diabetes Mellitus, Type 2; Pioglitazone; Urinary Bladder Neoplasms; Korea

MeSH Terms

Aged
Asian Continental Ancestry Group
Case-Control Studies
Cohort Studies
Diabetes Mellitus, Type 2/complications/*drug therapy
Female
Humans
Hypoglycemic Agents/*therapeutic use
Male
Middle Aged
Prevalence
Republic of Korea
Retrospective Studies
Risk Factors
Tertiary Care Centers
Thiazolidinediones/*therapeutic use
Urinary Bladder Neoplasms/complications/*diagnosis/epidemiology
Hypoglycemic Agents
Thiazolidinediones

Reference

1. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012; 344:e3645.

2. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34:916–922.

3. Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012; 104:1411–1421.

4. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012; 55:1953–1962.

5. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012; 35:278–280.

6. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012; 184:E675–E683.

7. Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013; 30:1026–1032.

8. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012; 98:159–163.

9. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999; 1:330–339.

10. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H, Nakatani T. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003; 104:597–602.

11. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci. 2010; 113:349–357.

12. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011; 54:2009–2015.

13. Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013; 99:e21–e23.

14. Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 2012; 36:371–378.